Survival Benefit and Efficacy of Gefitinib in Recurrent/Metastatic Head and Neck Cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Survival Benefit and Efficacy of Gefitinib in Recurrent/Metastatic Head and Neck Cancer ; volume:28 ; number:03 ; year:2007 ; pages:5-10
Indian journal of medical & paediatric oncology ; 28, Heft 03 (2007), 5-10
- Beteiligte Personen und Organisationen
-
Rao, R. Ranga
Konnpal, Anil
Bansal, Lalit
Dhiman, Amit
Khatri, Sameer
Rawat, Shneh
Dewan, Ajay
- DOI
-
10.1055/s-0041-1733221
- URN
-
urn:nbn:de:101:1-2022042811393205893961
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Rao, R. Ranga
- Konnpal, Anil
- Bansal, Lalit
- Dhiman, Amit
- Khatri, Sameer
- Rawat, Shneh
- Dewan, Ajay
Ähnliche Objekte (12)
Gefitinib-induced skin ulceration in metastatic adenocarcinoma lung
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
Benefit of salvage total pharyngolaryngoesophagectomy for recurrent locally advanced head and neck cancer after radiotherapy
Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer
Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer
Gefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coatingGefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coating
Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma
Recurrent neck myxofibrosarcoma: a case report
First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048
Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck: A Tertiary Cancer Center Experience
Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma
Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma
Gefitinib-induced skin ulceration in metastatic adenocarcinoma lung
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
Benefit of salvage total pharyngolaryngoesophagectomy for recurrent locally advanced head and neck cancer after radiotherapy
Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer
Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer
Gefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coatingGefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coating
Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma
Recurrent neck myxofibrosarcoma: a case report
First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048
Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck: A Tertiary Cancer Center Experience
Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma
Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma
Gefitinib-induced skin ulceration in metastatic adenocarcinoma lung
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
Benefit of salvage total pharyngolaryngoesophagectomy for recurrent locally advanced head and neck cancer after radiotherapy
Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer
Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer
Gefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coatingGefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coating
Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma
Recurrent neck myxofibrosarcoma: a case report
First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048
Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck: A Tertiary Cancer Center Experience
Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma